CRBU Company Profile and Key Details

Caribou Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.00. This means the shares are trading below this model’s fair value.

Caribou Biosciences, Inc. has 93.12 million shares outstanding. The public float is 84.06 million shares, elevated short interest at 4.53% of float. This equals 4.03 million shares. The short ratio is 3.53 days. Institutional investors hold 47.01% of the float. Insiders own 9.81%. Caribou Biosciences, Inc. holds 3.99 million shares, Haurwitz Rachel E. has 3.37 million shares and MCCLUNG BARBARA G has 443.50 thousand shares.

Caribou Biosciences, Inc. generated EPS of -$1.70 over the past year. Five-year average earnings growth is -33.41%. Wall Street analysts project EPS growth of 7.32% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.31. Next year's EPS is expected at -$23.53. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $3.00. The high target offers 638.64% upside. The low target suggests 70.45% downside. The mean target is $8.40. This offers 377.27% upside. Caribou Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -17.98%. The prior quarter beat by -12.5%. Over the last six quarters, Apple has recorded several small beats. These include -6.67% in August 06, 2024.

Caribou Biosciences, Inc. (NASDAQ:CRBU) closed at $1.76 USD, gaining $0.14 (8.64%) from the previous close of $1.62. The stock is currently mid-range between its 52-week high and low $0.66 and $3.54. With a market capitalization of about $164.50 million, Caribou Biosciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.61). Key stats such as the average daily volume over the past year has been around 1.07 million shares, in line with its 52-week average. Headquartered in Berkeley, CA, Caribou Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rachel E. Haurwitz, the company employs approximately 147 people and listed since July 23, 2021. Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.

Caribou Biosciences, Inc. trades at a P/E ratio of -0.96, slightly below the S&P 500 average, with a price-to-sales ratio of 16.24 and a price-to-book ratio of 1.06 suggesting the stock is closer to book value. The P/FCF stands at -1.18, also above market averages.

Our AI price prediction model suggests that Caribou Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.52%, with price expected at $1.61 by March 04, 2026, within a range of $1.52 to $1.69 3-Month Outlook: Projected fall of -81.25%, reaching $0.33 by May 19, 2026, with a range of $0.25 to $0.40. 1-Year Outlook: Projected gain of 228.98%, with price at $5.79 by February 18, 2027, within a range of $0.00 to $8.81.

Caribou Biosciences, Inc. (NASDAQ:CRBU) shares are down -12.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Caribou Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.96. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.73, suggesting 907.39% upside. Our AI forecast model points to short-term weakness (-8.52% over two weeks), a medium-term fall (-81.25% over three months), and a longer-term gain (228.98% over one year), with expected trading ranges indicating moderate volatility.